Biallelic correction of sickle cell disease‐derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum‐free iPS‐sac/erythroid differentiation

Biallelic correction of sickle cell disease‐derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum‐free iPS‐sac/erythroid differentiation

Abstract New technologies of induced pluripotent stem cells (iPSCs) and genome editing have emerged, allowing for the development of autologous transfusion therapies. We previously demonstrated definitive β‐globin production from human embryonic stem cell (hESC)‐derived erythroid cell generation via...

Full description

Bibliographic Details
Main Authors: Juan J. Haro‐Mora, Naoya Uchida, Selami Demirci, Qi Wang, Jizhong Zou, John F. Tisdale
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Stem Cells Translational Medicine
Subjects:
genome editing
hematopoiesis
hESCs
iPSCs
serum‐free
sickle cell disease
Online Access:https://doi.org/10.1002/sctm.19-0216

Internet

https://doi.org/10.1002/sctm.19-0216

Similar Items